PDCD1 and cancer: PD-L1 expression is upregulated in various types of cancers and it was found to correlate with lower overall survival and disease-free survival in human malignant tumours, suggesting that it may be one of the ways to predict clinical outcomes after anti-PD-1/PD-L1 therapy [16].